Evidence map›Paper›PMID 37974628›Full record

ArticleACS pharmacology & translational science2023

Small-Molecule Activation of Protein Phosphatase 2A Counters Bleomycin-Induced Fibrosis in Mice.

Meshach Pillai, Pascale Lafortune, Abdoulaye Dabo, Howard Yu, Sangmi S Park, Harsha Taluru, Huma Ahmed, Dylan Bobrow, Zeeshan Sattar, Bakr Jundi and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Meshach PillaiDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Pascale LafortuneDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Abdoulaye DaboDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Howard YuDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Sangmi S ParkDepartment of Cell Biology, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Harsha TaluruDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Huma AhmedDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Dylan BobrowDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Zeeshan SattarDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Bakr JundiDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Joshua ReeceDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Romy Rodriguez OrtegaDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Brian SotoDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Selome YewedalsewDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Robert ForonjyDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Anne WymanDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.
Patrick GeraghtyDepartment of Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, New York 11203, United States.ORCID https://orcid.org/0000-0003-1647-5505
Michael OhlmeyerAtux Iskay LLC, Plainsboro, New Jersey 08536, United States.ORCID https://orcid.org/0000-0003-1412-543X
State University of New York · USPrinceton Satellite Systems (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The activity of protein phosphatase 2A (PP2A), a serine-threonine phosphatase, is reduced in the lung fibroblasts of idiopathic pulmonary fibrosis (IPF) patients. The objective of this study was to determine whether the reactivation of PP2A could reduce fibrosis and preserve the pulmonary function in a bleomycin (BLM) mouse model. Here, we present a new class of direct small-molecule PP2A activators, diarylmethyl-pyran-sulfonamide, exemplified by ATUX-1215. ATUX-1215 has improved metabolic stability and bioavailability compared to our previously described PP2A activators. Primary human lung fibroblasts were exposed to ATUX-1215 and an older generation PP2A activator in combination with TGFβ. ATUX-1215 treatment enhanced the PP2A activity, reduced the phosphorylation of ERK and JNK, and reduced the TGFβ-induced expression of

Identifiers

PMID37974628
PMCPMC10644462
OpenAlexW4387694223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.